Ardent Health Partners, LLC
NYSE:ARDTMedical - Care Facilities
-$0.14 today
- Market cap
- $2.03B
- Beta
- 0.84
- P/E (TTM)
- 9.4
- EPS (TTM)
- $0.95
Volume 7.27M
Average 0.45M
ARDT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Ardent Health Partners, LLCNYSE: ARDT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 23.2% from a year ago
Cash & equivalents stood at $609.69M at the end of Q1 FY2026, up 23.2% from a year earlier and down 14.1% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Cash & equivalents amounted to 11.6% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +23.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 709.6M USD
- Year-over-year change
- +27.4%
- 7-year CAGR
- +42.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 709.6M | +27.4% |
| FY2024 | 2024-12-31 | 556.79M | +27.2% |
| FY2023 | 2023-12-31 | 437.58M | -4.1% |
| FY2022 | 2022-12-31 | 456.12M | — |
| FY2018 | 2018-12-31 | 59.66M | — |
Cash & Equivalents vs competitors
How ARDT compares with its peers on the latest reported figures
- ARDT's Mar 2026 cash & equivalents of $609.69M is the highest of the 11 companies compared; the peer median is $180.58M.
- Its year-over-year change of +23.2% is the 5th highest of 11, against a peer median of +14.4%.
- Cash & equivalents amounts to 11.6% of total assets for ARDT, versus a peer median of 7.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ARDTArdent Health Partners, LLC | Mar 2026 | $609.69M | +23.2% | +15.9% | 11.6% |
| Mar 2026 | $478.38M | +85.0% | +14.2% | 20.3% | |
| Sep 2026 | $323.37M | +27.6% | -11.2% | 5.5% | |
| Sep 2026 | $311.92M | -8.3% | +236.8% | 14.6% | |
| Jun 2026 | $225.94M | +19.6% | +31.8% | 10.4% | |
| Oct 2026 | $197.84M | +35.6% | +115.9% | 9.0% | |
| Sep 2026 | $163.31M | +37.6% | +10.9% | 2.9% | |
| Jun 2026 | $99.57M | +9.2% | +0.7% | 6.8% | |
| Sep 2026 | $66.8M | -48.9% | +23.7% | 3.2% | |
| Sep 2026 | $45.08M | -25.2% | -5.5% | 7.4% | |
| Mar 2026 | $25.68M | -51.7% | -35.3% | 0.4% | |
| Peer median (excluding ARDT) | $180.58M | +14.4% | +12.6% | 7.1% | |
Competitors are the stored peer set for ARDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2018 Dec 2018 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.66M | 456.12M | 437.58M | 556.79M | 709.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 529.12M | 611.96M | 785.76M | 743.03M | 686.1M |
| Inventory | 84.81M | 107.15M | 105.49M | 115.09M | 118.59M |
| Other Current Assets | 100.57M | 165.05M | 211.99M | 304.09M | 544.53M |
| Total Current Assets | 860.42M | 1.41B | 1.62B | 1.83B | 2.06B |
| Property, Plant & Equipment (Net) | 839.89M | 1.99B | 2.01B | 2.04B | 2.14B |
| Goodwill | 822.03M | 844.7M | 844.7M | 852.08M | 879.45M |
| Intangible Assets | 77.83M | 76.93M | 76.93M | 76.93M | 89.34M |
| Long-term Investments | 0 | 29.4M | 17.8M | 11.46M | 0 |
| Tax Assets | 95.99M | 415.46M | 403.7M | 12.32M | 6.89M |
| Other Non-current Assets | 50.11M | 93.98M | 129.31M | 131.51M | 111.69M |
| Total Non-current Assets | 1.89B | 3.45B | 3.48B | 3.12B | 3.23B |
| Total Assets | 2.75B | 4.86B | 5.1B | 4.96B | 5.29B |
| Account Payables | 230.36M | 320.8M | 474.54M | 401.25M | 457.94M |
| Short-term Debt | 8.96M | 58.42M | 61.03M | 9.23M | 23.44M |
| Tax Payables | 14.84M | 17.35M | 18.02M | 15.2M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 190.75M | 167.84M | 172.83M | 44.66M | 565.16M |
| Total Current Liabilities | 624.83M | 808.6M | 994.1M | 945.42M | 1.05B |
| Long-term Debt | 1.25B | 1.15B | 1.15B | 1.07B | 1.08B |
| Deferred Tax Liabilities | 0 | 381.03M | 371.21M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 157.7M | 290.01M | 319.55M | 261.75M | 317.69M |
| Total Non-current Liabilities | 1.41B | 3B | 3.03B | 2.49B | 2.56B |
| Total Liabilities | 2.03B | 3.81B | 4.02B | 3.43B | 3.61B |
| Common Stock | 504.69M | 510.97M | 496.88M | 1.43M | 1.43M |
| Retained Earnings | (167.16M) | 101.55M | 155.45M | 365.8M | 501.61M |
| Accumulated OCI | (5.89M) | 26.53M | 18.56M | 9.74M | (3.61M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 1.19B |
| Minority Interest | 380.19M | 411.26M | 411.42M | 390.98M | (1.25M) |
| Total Equity | 711.84M | 1.05B | 1.08B | 1.52B | 1.68B |
| Total Debt | 1.26B | 2.39B | 2.4B | 2.28B | 2.26B |
| Net Debt | 1.2B | 1.93B | 1.96B | 1.73B | 1.55B |
Ardent Health Partners, LLC
NYSE:ARDT
Intrinsic Alpha fair value
Locked
Current Price
$14.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.